ID: ALA2413529

Max Phase: Preclinical

Molecular Formula: C20H34N2O6

Molecular Weight: 398.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCOCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C20H34N2O6/c1-2-3-4-5-6-7-8-9-10-27-14-15-12-22(20(26)21-19(15)25)18-11-16(24)17(13-23)28-18/h12,16-18,23-24H,2-11,13-14H2,1H3,(H,21,25,26)/t16-,17+,18+/m0/s1

Standard InChI Key:  SIOHQGWTNVEBRI-RCCFBDPRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 398.50

Molecular Weight (Monoisotopic): 398.2417

AlogP: 1.83

#Rotatable Bonds: 13

Polar Surface Area: 113.78

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.59

CX Basic pKa:

CX LogP: 2.23

CX LogD: 2.23

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.44

Np Likeness Score: 0.47

References

1. Shmalenyuk ER, Chernousova LN, Karpenko IL, Kochetkov SN, Smirnova TG, Andreevskaya SN, Chizhov AO, Efremenkova OV, Alexandrova LA..  (2013)  Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.,  21  (17): [PMID:23891229] [10.1016/j.bmc.2013.07.003]

Source

Source(1):

• Scientific Literature